New drug aims to boost Cancer-Killing power of CAR-T therapy
NCT ID NCT07361224
Summary
This early-stage study is testing the safety of adding an experimental drug called CLS-015 to standard CAR-T cell therapy for adults with large B-cell lymphoma. It focuses on patients whose cancer is stable or growing just before their CAR-T treatment, a group with a high risk of the cancer returning quickly. The goal is to see if CLS-015 can make the CAR-T therapy work better and last longer by helping the immune cells fight the cancer more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.